Dedicated to transforming
cardiovascular muscle disease
Muscle moves us.
From inertia to innovation. From possibility to promise. From unmet need to novel therapies.
At Edgewise, we’re bringing our unique expertise to develop novel therapeutics for serious cardiovascular diseases – with determination, integrity and a strong commitment to patients.
Learn more about how our science is driving a new understanding of cardiac muscle and its potential to transform human health.
Our Focus:
Serious Cardiovascular Diseases With Life-limiting Impact
Hypertrophic Cardiomyopathy (HCM)
HCM is the most prevalent inherited cardiomyopathy. It is characterized by excessive thickening of the left ventricular wall, which can lead to life-altering symptoms and limitations in daily activities.
Heart Failure (HF)
Heart failure, including heart failure with preserved ejection fraction (HFpEF), is a highly prevalent cardiovascular disease often associated with a stiffened heart muscle that can significantly impact daily life.
Inspired by
patients and families
We honor the experience of individuals and families living with and facing the challenges of serious cardiovascular disease. Our commitment to bringing life-changing medicines is inspired by their strength and courage.
Science Driven.
Patient commitment.
Our science-driven culture places patients first as we start with their unmet need then work towards developing therapies to help address the significant challenges of serious cardiovascular diseases.
Add muscle to your career
We built a company that’s inspirational, pioneering, science-forward and always reaching new heights. Learn more about what it’s like to work with us—globally or at our headquarters—and elevate your career to the next level.
Latest News
Jul. 13, 2026
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Jul. 1, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Jun. 16, 2026
